Background: Obesity is a risk factor for numerous cancer types, and may influence cancer treatment outcomes. Underrepresentation of obese patients in obesity-related cancer randomized controlled trials (RCTs) may affect generalizability of results. We aimed to assess the reporting of information about eligibility and enrollment of obese participants in obesityrelated cancer RCTs.
Introduction
Cancer is one of the leading causes of death worldwide [1] . The prevalence of obesity has increased dramatically since 1980 globally [2] . In the United States, the age-standardized prevalence of obesity was 35% in men and 40% in women for 2013-2014 [3] . There is now strong evidence that obesity is associated with increased risk of developing a number of cancer types [4] [5] [6] . Potential mechanisms involve increased levels of sex hormones, oversecretion of deleterious adipokines, elevated insulin and insulin-like growth factor-I levels, or chronic inflammation causing DNA damage [7, 8] . The population attributable fraction of high body mass index (BMI) with respect to obesity-related cancers is 11.9% in men and 13.1%, globally [9] . Cancer types associated with overweight and obesity represented about 40% of all cancers diagnosed in the United States in 2014 [10] .
There is also accumulating evidence that obesity may be associated with poorer outcomes for specific cancer types, including increased risk of progression, recurrence, and death [11, 12] . Obesity also has potential consequences on clinical management, by influencing treatment selection and outcomes [13, 14] . BMI may be a treatment effect modifier because of differences in biological processes, pharmacodynamics/pharmacokinetics, or dose specifications [13, [15] [16] [17] . In particular, flat-dose rather than weight-based regimens are increasingly being used for targeted therapies and immunotherapies, but increased BMI may lead to underdosing [18] [19] [20] . If obese people are poorly represented, cancer randomized controlled trials (RCTs) may fail to provide adequate information to judge the effect of treatments and dosing in real world settings. Our objective was to assess the reporting of information about eligibility and enrollment of obese participants in obesity-related cancer RCTs.
Methods

Selection criteria for trials
We searched for RCTs published between 2013 and 2016. We excluded reports of phase I, II and IV trials; palliative care, supportive care and prevention trials; secondary, follow-up, and subgroup analyses; and metaanalyses or pooled analyses. We selected the reports in the Journal of Clinical Oncology, Lancet Oncology, New England Journal of Medicine, The Lancet, and JAMA. We chose these journals because they publish cancer RCTs and their protocols. We selected only trials in adults. We focused on RCTs of the following obesity-related cancer types: esophagus, colon/ rectum, liver, gallbladder, pancreas, postmenopausal breast, endometrium, ovary, kidney, and thyroid. Trials for gastroesophageal cancer were excluded. The included cancer types were selected on the basis of the evidence showing that obesity is a risk factor for each of these cancer types [4, 6] .
Search and selection of trials
We searched MEDLINE with separate search equations for each of the 10 cancer types (supplementary Appendix 1, available at Annals of Oncology online). Two authors independently screened titles and abstracts, and then full-text articles. Any disagreements were discussed among the two authors to resolve differences. For each selected trial, we searched for a registration record and for a protocol.
Data collection
We collected general trial characteristics, including the cancer type, sample size, trial design, and type of experimental arm. We classified trials as enrolling in the United States and Canada only, enrolling in the United States and Canada as well as other countries, and not enrolling in the United States or Canada. To determine the funding source, we extracted information from the main text, funding support description, authors' affiliations and acknowledgement sections of the article. We categorized the funding source into industry-funded (partially or fully) and nonindustry-funded.
To exclude the possibility that potential underrepresentation would be explained by formal selection of patients, we then documented if the eligibility criteria restricted the enrollment of obese participants. We considered enrollment to be restricted if a range of weight or BMI was used for study inclusion or exclusion. We also checked the registration record and the protocol, when available, for inclusion and exclusion criteria based on BMI. We collected the proportion of obese participants among randomized participants and the mean and standard deviation for BMI. Obesity was defined as a BMI of 30.0 kg/m 2 or greater consistent with WHO guidelines. We also searched for this information when trial results had been posted on the registration record. Finally, we assessed if a subgroup analysis according to BMI or obesity status was available. We categorized each trial into excluding obese participants, including obese participants, and not specifying. Not specifying inclusion or exclusion of obese participants is the same as allowing enrollment of obese participants.
Two authors extracted the data in duplicate on all the reports. Discrepancies were discussed among the two authors to reach consensus.
Email survey to corresponding authors
We systematically contacted corresponding authors by email. We asked if obese participants were eligible in their trials and what proportion of enrolled participants were obese. Finally, we asked for the mean and standard deviation of BMI of the trial participants. We sent two reminder emails, 1 and 2 weeks after the initial correspondence.
Eligibility and representation of obese participants in selected trials
If the number of obese participants was missing but the mean and standard deviation (SD) of BMI were available, we used them to estimate the proportion of obese participants. We assumed that BMI followed a normal distribution and estimated the probability that the BMI was larger than 30 kg/m 2 . We first analyzed the eligibility and representation of obese participants based on published information only to reflect the reader's point of view. Then, we repeated this assessment by using the published information combined with data obtained via email survey correspondence. Finally, we assessed the representation of obese participants according to funding source, trial size, and cancer types.
Results
Selection and characteristics of clinical trials
We included 76 trials in this analysis (Figure 1 ; references in supplementary Appendix 2, available at Annals of Oncology online). Of the 76 trials, we found a registration record for every trial, and we found published protocols for 42 (55.2%) of the trials. The three most represented cancer types in the trials were colon/rectum (n ¼ 20), breast (n ¼ 11), and kidney (n ¼ 11) ( Table 1 ). The majority of the trials included participants in the United States and Canada (63.2%), 10 of which occurred only in the United States and Canada. A pharmaceutical company was involved in 63 (82.9%) trials, either fully or partially funding the research.
Eligibility of obese participants
Based on publicly available information, 5 (6.6%) trials included obese participants, no trials excluded obese participants, and 71 did not specify inclusion or exclusion of obese participants. Of the five trials that included obese participants, the information was available in the article, protocol, and registration record for one of the trials. Although this trial restricted enrollment to individuals with a BMI less than or equal to 34 kg/m 2 , we considered this trial to include obese participants since it considered participants with BMI between 30 and 34 kg/m 2 as eligible. For another trial, the protocol and registration record mentioned that the randomization would be stratified according to BMI (<30 kg/m 2 versus 30 kg/m 2 ); the article also mentioned the number of obese participants. For the other three trials, the article reported the number of obese participants they enrolled, all of which were greater than zero.
We obtained unpublished information through our survey regarding the eligibility of obese participants for an additional 26 trials (supplementary Appendix 3, available at Annals of Oncology online). All respondents indicated that obese participants were eligible. When considering the survey information in addition to the publically available information, at least 31 of 76 (40%) of the trials would have allowed for patients to participate regardless of BMI.
Representation of obese participants
The proportion of obese participants was reported in the article for 4 (5.3%) trials; moreover, four trials reported the mean and SD of BMI, allowing us to estimate the proportion of obese participants. Trial results were posted on clinicaltrials.gov for 32 (42.1%) trials; none reported the proportion of obese participants, but one provided the mean and SD of BMI. In all, these 9 trials enrolled a total of 10 875 participants, among which 2865 (26.3%) participants were obese. The median proportion of obese participants was 19.1% (Q1-Q3 11.0-23.2) (Figure 2A) .
Through email correspondence, unpublished information on the proportion of obese participants was obtained for 12 additional trials, and was derived from the mean and SD of BMI for 1 additional trial. Of note, BMI data were not collected for eight trials, according to the corresponding authors. In all, we obtained estimates of the proportion of obese participants in 22 (28.9%) trials. These 22 trials enrolled a total of 26 566 participants, among which 5461 (20.6%) participants were obese. The median proportion of obese participants included in these 22 trials was 17.9% (Q1-Q3 11.3-22.7).
We found a subgroup analysis examining the treatment effect in obese and nonobese participants in only 1 trial (reference 58 in supplementary Appendix 2, available at Annals of Oncology online). The experimental treatment was less successful in obese patients as compared with nonobese patients, although there was no evidence of statistically significant interaction (P ¼ 0.16).
Representation of obese participants according to trial funding, size, and cancer type Across the 22 trials with available data, there was no evidence of difference in the proportion of obese participants between nonindustry-supported trials as compared with industrysponsored trials (n ¼ 7, median 12.0% (Q1-Q3 7.3-20.3) versus n ¼ 15, median 19.1% (Q1-Q3 14.4-24.0), Mann-Whitney test P ¼ 0.17, Figure 2B ). Moreover, there was a positive relationship between the trial size and the enrollment of obese participants, with larger trials enrolling larger proportions of obese participants ( Figure 2C ). Finally, we show the proportions of obese participants across different cancer types ( Figure 2D ).
Discussion
In this systematic review of obesity-related cancer RCTs, we found a dramatic underreporting of information regarding the eligibility and enrollment of obese participants. Although obesity was never listed as an exclusion criterion, whether obese participants were eligible to participate was unclear in 93% of trials, after examination of the article, protocol, and registration record. We can surmise that, if no exclusion criteria based on BMI was reported, obese participants were eligible. But the proportion of obese participants enrolled in the trial was not reported in 95% of trials. Finally, we obtained data for 29% of the 76 selected trials and the median proportion of obese participants was 18%.
The lack of information regarding enrollment of obese participants stands in sharp contrast with the expanding real-world concern of obesity in cancer and ongoing reflections about improving the assessment drugs' safety and efficacy in patients who will ultimately receive them [21] [22] [23] [24] . Given the role of obesity in shaping cancer risks and outcomes, our results highlight the critical need to improve the reporting of obesity status information. We obtained estimates of the proportion of obese participants for less than one-third of our sample of cancer RCTs. It is then difficult to draw any firm conclusion regarding the underrepresentation of obese participants. We cautiously assert that the observed proportions were low overall. According to a review informing the management of obese patients with cancer, the proportions of patients with obesity are high (endometrial, 39%-47%; renal cell carcinoma, 42%; rectal, 18%-37%; esophageal adenocarcinoma, 35%) [13] . In the United States, the prevalence of obesity in adults with a history of cancer has increased from 22.4% in 1007 to 31.7% in 2014 [25] . These figures may underestimate the lifetime prevalence of obesity in cancer patients as the onset of cancer is often accompanied by unintentional weight loss [26] .
Previous studies have shown that racial and ethnic minorities are underrepresented in trials of cancer treatment [27] [28] [29] [30] . There is also some evidence to suggest that cancer trials have become less representative of patients with comorbidities [31] . The poor representation of racial/ethnic minorities or patients with comorbidities is consistent with a potential underrepresentation of obese patients with cancer in trials. In 2011-2012, non-Hispanic blacks and Hispanics had the highest prevalence of obesity in the United States (47.8% and 42.0%, respectively) [32] . In addition, obesity is a risk factor for the development of comorbid illness [33] . Finally, obese patients may be less likely than nonobese patients to be offered trial participation, because of unconscious weight biases [34, 35] or because of mediation through race/ethnicity [36, 37] .
Our study has limitations. Our review did not cover trials of multiple myeloma or leukemia for which convincing evidence is now available [38] . Moreover, our prespecified methods focused on obesity and we did not assess the representation of overweight participants. In addition, our sample of trials is relatively small and we have focused on articles published in high-impact journals, which limits the generalizability of the results. We have focused our analysis on primary articles, excluding secondary and follow-up analyses. We cannot exclude that information on obese participants is reported in secondary articles. Finally, we have focused on BMI to define obesity. Other measurements may be essential to improve the management of obese patients with cancer. In particular, weight loss in patients with cancer results in sarcopenia; obese patients may have substantial muscle depletion, which could be a biomarker for drug adverse effects [13, 14] .
Conclusion
In conclusion, we have found that articles reporting RCT results provide scant information about the eligibility of obese patients and the number of obese patients actually enrolled. Transparency in participant information is needed to understand participation of obese people in cancer clinical trials and applicability of results to obese patients with cancer.
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